The IFOPA is pleased to share these announcements from the Perelman School of Medicine/University of Pennsylvania Health System and Clementia Pharmaceuticals sharing results of a study conducted by researchers at Penn Medicine and Children’s Hospital of Philadelphia (CHOP) on the effects of palovarotene in an animal model of Fibrodysplasia Ossificans Progressiva (FOP).
Please click these links to learn more:
Perelman School of Medicine/University of Pennsylvania Health System
Learning more about Palovarotene: An Editorial for the FOP Community
Do you like this post?